Targeting sphingosine-1-phosphate signalling for cardioprotection

S. Kennedy, K.A. Kane, N.J. Pyne, S. Pyne

Research output: Contribution to journalLiterature review

27 Citations (Scopus)

Abstract

Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK1 or SK2)-catalysed phosphorylation of sphingosine. Plasma S1P is carried in high-density lipoprotein (HDL) or bound to albumin and is reported to arise from activated platelets and erythrocytes. In addition, extracellular SK1 released from vascular endothelial cells may also contribute to plasma S1P levels. S1P exerts its effects through a family of five high affinity S1P-specific G protein-coupled receptors (GPCRs), S1P1-5. Various S1P receptors are present in the cardiovascular system, including cardiac tissue. Additionally, intracellular S1P may have a second messenger action. Since S1P is recognised as a survival factor in many tissues, there has been much interest in S1P as a cardioprotective agent. Recent evidence indicates that S1P can pre-condition and post-condition the heart and that the cardioprotective effect of HDL may be because of its S1P content. In addition, evidence is emerging that the cardioprotective effects of cannabinoids and S1P may be linked.
LanguageEnglish
Pages194-201
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume9
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

HDL Lipoproteins
sphingosine 1-phosphate
Lysosphingolipid Receptors
Lysophospholipids
Cardiotonic Agents
Sphingosine
Cannabinoids
Second Messenger Systems
G-Protein-Coupled Receptors
Cardiovascular System
Albumins
Blood Platelets
Endothelial Cells
Erythrocytes
Phosphorylation
sphingosine kinase

Keywords

  • sphingosine-1-phosphate
  • S1P
  • high-density lipoprotein
  • cardioprotection
  • cardiac tissue
  • HDL

Cite this

@article{70b5026159e7407cb9d060e07a1621e3,
title = "Targeting sphingosine-1-phosphate signalling for cardioprotection",
abstract = "Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK1 or SK2)-catalysed phosphorylation of sphingosine. Plasma S1P is carried in high-density lipoprotein (HDL) or bound to albumin and is reported to arise from activated platelets and erythrocytes. In addition, extracellular SK1 released from vascular endothelial cells may also contribute to plasma S1P levels. S1P exerts its effects through a family of five high affinity S1P-specific G protein-coupled receptors (GPCRs), S1P1-5. Various S1P receptors are present in the cardiovascular system, including cardiac tissue. Additionally, intracellular S1P may have a second messenger action. Since S1P is recognised as a survival factor in many tissues, there has been much interest in S1P as a cardioprotective agent. Recent evidence indicates that S1P can pre-condition and post-condition the heart and that the cardioprotective effect of HDL may be because of its S1P content. In addition, evidence is emerging that the cardioprotective effects of cannabinoids and S1P may be linked.",
keywords = "sphingosine-1-phosphate, S1P, high-density lipoprotein, cardioprotection, cardiac tissue, HDL",
author = "S. Kennedy and K.A. Kane and N.J. Pyne and S. Pyne",
year = "2009",
month = "4",
doi = "10.1016/j.coph.2008.11.002",
language = "English",
volume = "9",
pages = "194--201",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
number = "2",

}

Targeting sphingosine-1-phosphate signalling for cardioprotection. / Kennedy, S.; Kane, K.A.; Pyne, N.J.; Pyne, S.

In: Current Opinion in Pharmacology, Vol. 9, No. 2, 04.2009, p. 194-201.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Targeting sphingosine-1-phosphate signalling for cardioprotection

AU - Kennedy, S.

AU - Kane, K.A.

AU - Pyne, N.J.

AU - Pyne, S.

PY - 2009/4

Y1 - 2009/4

N2 - Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK1 or SK2)-catalysed phosphorylation of sphingosine. Plasma S1P is carried in high-density lipoprotein (HDL) or bound to albumin and is reported to arise from activated platelets and erythrocytes. In addition, extracellular SK1 released from vascular endothelial cells may also contribute to plasma S1P levels. S1P exerts its effects through a family of five high affinity S1P-specific G protein-coupled receptors (GPCRs), S1P1-5. Various S1P receptors are present in the cardiovascular system, including cardiac tissue. Additionally, intracellular S1P may have a second messenger action. Since S1P is recognised as a survival factor in many tissues, there has been much interest in S1P as a cardioprotective agent. Recent evidence indicates that S1P can pre-condition and post-condition the heart and that the cardioprotective effect of HDL may be because of its S1P content. In addition, evidence is emerging that the cardioprotective effects of cannabinoids and S1P may be linked.

AB - Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK1 or SK2)-catalysed phosphorylation of sphingosine. Plasma S1P is carried in high-density lipoprotein (HDL) or bound to albumin and is reported to arise from activated platelets and erythrocytes. In addition, extracellular SK1 released from vascular endothelial cells may also contribute to plasma S1P levels. S1P exerts its effects through a family of five high affinity S1P-specific G protein-coupled receptors (GPCRs), S1P1-5. Various S1P receptors are present in the cardiovascular system, including cardiac tissue. Additionally, intracellular S1P may have a second messenger action. Since S1P is recognised as a survival factor in many tissues, there has been much interest in S1P as a cardioprotective agent. Recent evidence indicates that S1P can pre-condition and post-condition the heart and that the cardioprotective effect of HDL may be because of its S1P content. In addition, evidence is emerging that the cardioprotective effects of cannabinoids and S1P may be linked.

KW - sphingosine-1-phosphate

KW - S1P

KW - high-density lipoprotein

KW - cardioprotection

KW - cardiac tissue

KW - HDL

UR - http://www.journals.elsevier.com/current-opinion-in-pharmacology

U2 - 10.1016/j.coph.2008.11.002

DO - 10.1016/j.coph.2008.11.002

M3 - Literature review

VL - 9

SP - 194

EP - 201

JO - Current Opinion in Pharmacology

T2 - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 2

ER -